Nitrofurantoin Activase (Nitrofurantoin)

Nitrofurantoin is reduced inside bacterial cells to reactive intermediates that bind to bacterial ribosomal proteins and DNA. This disrupts carbohydrate metabolism and essential enzymatic processes, leading to rapid bactericidal activity against common urinary pathogens while having limited systemic absorption.

The specific dose and duration of therapy are determined by the prescribing clinician based on the infection severity, patient renal function, and local guidelines. Healthcare professionals should follow the product label and individual patient needs when prescribing.

Safety in pregnancy has not been fully established; nitrofurantoin is generally avoided in the later stages of pregnancy unless the benefit outweighs the risk. Limited data are available for breastfeeding, and caution is advised. Clinicians should evaluate maternal and fetal considerations before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nitrofurantoin offers a narrow spectrum of activity focused on common uropathogens and achieves high urinary concentrations, making it effective for uncomplicated infections. Compared with broader‑spectrum agents like trimethoprim‑sulfamethoxazole, it may have fewer systemic side effects but requires adequate renal function for optimal efficacy.

Store Nitrofurantoin Activase at room temperature, below 25 °C, in the original packaging. Protect the product from moisture and direct sunlight to maintain stability. Do not refrigerate or freeze unless specifically instructed on the label.

Nitrofurantoin Activase is taken orally, usually with food or a full glass of water to improve absorption and reduce gastrointestinal irritation. The exact administration schedule should follow the prescriber’s instructions and the product’s labeling.

Serious adverse reactions include pulmonary toxicity (interstitial lung disease), hepatic injury, hemolytic anemia in patients with G6PD deficiency, severe allergic reactions such as Stevens‑Johnson syndrome, peripheral neuropathy, and blood dyscrasias. Patients should be monitored for any signs of these conditions and seek immediate medical attention if they occur.

Nitrofurantoin Activase is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to nitrofurantoin, G6PD deficiency, and in late‑term pregnancy unless no alternative exists. Clinicians should assess each patient’s medical history before prescribing.